ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.068,21
0,26%
S&P 500
5.461,10
0,54%
Dow Jones
38.667,93
0,20%
Euro vs US Dollar
1,07241
0,06%
Bitcoin
66.012,09
-0,94%
Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Apogee Therapeutics Inc (APGE)

  7. Apogee Therapeutics Inc (APGE) News

APGE

Apogee Therapeutics (APGE)

Apogee Therapeutics Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:APGE
DatumZeitQuelleÜberschriftSymbolFirma
08/06/202402h04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
07/06/202422h02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APGEApogee Therapeutics Inc
31/05/202402h07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
31/05/202402h05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
28/05/202413h36Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:APGEApogee Therapeutics Inc
28/05/202413h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APGEApogee Therapeutics Inc
28/05/202413h30GlobeNewswire Inc.Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MDNASDAQ:APGEApogee Therapeutics Inc
23/05/202413h30GlobeNewswire Inc.Apogee Therapeutics to Participate in Upcoming June Investor ConferencesNASDAQ:APGEApogee Therapeutics Inc
15/05/202422h01GlobeNewswire Inc.Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory DiseasesNASDAQ:APGEApogee Therapeutics Inc
13/05/202413h26Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:APGEApogee Therapeutics Inc
13/05/202413h10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:APGEApogee Therapeutics Inc
13/05/202413h05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APGEApogee Therapeutics Inc
13/05/202413h00GlobeNewswire Inc.Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
06/05/202414h00GlobeNewswire Inc.Apogee Therapeutics to Participate at the 2024 Bank of America Healthcare ConferenceNASDAQ:APGEApogee Therapeutics Inc
25/03/202412h00GlobeNewswire Inc.Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory DiseasesNASDAQ:APGEApogee Therapeutics Inc
12/03/202421h01GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 MillionNASDAQ:APGEApogee Therapeutics Inc
11/03/202411h01Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:APGEApogee Therapeutics Inc
08/03/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:APGEApogee Therapeutics Inc
08/03/202400h49GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public OfferingNASDAQ:APGEApogee Therapeutics Inc
08/03/202400h27Edgar (US Regulatory)Form S-1MEF - Registration adding securities to prior Form S-1 registration [Rule 462(b)]NASDAQ:APGEApogee Therapeutics Inc
05/03/202422h23GlobeNewswire Inc.Apogee Therapeutics, Inc. Announces Proposed Underwritten Public OfferingNASDAQ:APGEApogee Therapeutics Inc
05/03/202422h05Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:APGEApogee Therapeutics Inc
05/03/202414h15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APGEApogee Therapeutics Inc
05/03/202412h15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:APGEApogee Therapeutics Inc
05/03/202412h11Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:APGEApogee Therapeutics Inc
05/03/202412h10GlobeNewswire Inc.Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:APGEApogee Therapeutics Inc
05/03/202412h00GlobeNewswire Inc.Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of SchNASDAQ:APGEApogee Therapeutics Inc
04/03/202422h01GlobeNewswire Inc.Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024NASDAQ:APGEApogee Therapeutics Inc
02/01/202413h30GlobeNewswire Inc.Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:APGEApogee Therapeutics Inc
21/12/202302h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:APGEApogee Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:APGE

Kürzlich von Ihnen besucht

USOTC
BASFY
BASF (QX)
NYSE
JPM
JP Morgan Chase
TG
NOV
Novo Nordisk
FX
EURUSD
Euro vs US Dollar
USOTC
BNPQY
BNP Paribas (QX)
NYSE
DIS
Walt Disney
DBI
DAX
DAX
FX
EURGBP
Euro vs Sterling
NYSE
KO
Coca Cola
COIN
ETHUSD
Ethereum
NASDAQ
GOOGL
Alphabet
NASDAQ
AAPL
Apple
COIN
BTCUSD
Bitcoin
TG
D7G
Nel ASA
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten